- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Patent holdings for IPC class A61P 3/10
Total number of patents in this class: 13444
10-year publication summary
|
422
|
638
|
903
|
860
|
1014
|
1020
|
944
|
949
|
932
|
677
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Eli Lilly and Company | 4101 |
198 |
| Boehringer Ingelheim International GmbH | 4486 |
158 |
| Novo Nordisk A/S | 2284 |
128 |
| Janssen Pharmaceutica N.V. | 3160 |
106 |
| Takeda Pharmaceutical Company Limited | 2700 |
106 |
| F. Hoffmann-La Roche AG | 7808 |
105 |
| Pfizer Inc. | 3409 |
87 |
| The Regents of the University of California | 20815 |
84 |
| Daiichi Sankyo Company, Limited | 1891 |
81 |
| Sanofi | 4319 |
79 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 876 |
77 |
| Shionogi & Co., Ltd. | 883 |
75 |
| Société des Produits Nestlé S.A. | 10042 |
66 |
| Sunshine Lake Pharma Co., Ltd. | 629 |
63 |
| The Board of Trustees of the Leland Stanford Junior University | 6687 |
57 |
| Bristol-myers Squibb Company | 4757 |
53 |
| Merck Sharp & Dohme LLC | 3737 |
52 |
| Novartis AG | 10173 |
51 |
| Merck Sharp & Dohme Corp. | 2183 |
50 |
| President and Fellows of Harvard College | 6105 |
49 |
| Other owners | 11719 |